A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Type 1 diabetes (T1D) is caused by immune-mediated destruction of insulin-producing β-cells. Insufficient control of autoreactive T cells by regulatory T cells (Tregs) is believed to contribute to disease pathogenesis, but changes in Treg function are difficult to quantify because of the lack of Treg-exclusive markers in humans and the complexity of functional experiments. We established a new way to track Tregs by using a gene signature that discriminates between Tregs and conventional T cells regardless of their activation states. The resulting 31-gene panel was validated with the NanoString nCounter platform and then measured in sorted CD4+CD25hiCD127lo Tregs from children with T1D and age-matched control subjects. By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean ± SD 0.86 ± 0.14) and specific (0.78 ± 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. These findings provide new insight into the mechanisms underlying the failure to control autoimmunity in T1D and might lead to a biomarker test to monitor Tregs throughout disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently the only way to confidently quantify human Tregs is to use a panel of different markers and then carry out parallel functional [381], gene expression [382], and/or epigenetic analyses [383, 384].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [382]
Citations
Cites
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291 · cited 1×
“Previous attempts to define specific markers of human Tregs focused on comparing CD25 and CD25(2) cells (11,12,21,22), thereby introducing bias toward identifying T-cell activation/memory markers rather than Tregs.”
BackgroundReich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,032
Defective Suppressor Function in CD4+CD25+ T-Cells From Patients With Type 1 Diabetes
Lindley, S., Dayan, C. M., Bishop, A., Roep, B. O., Peakman, M., & Tree, T. I. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.92 · Cited by 861 · cited 1×
“Whether peripheral T1D Tregs are able to suppress effector cell proliferation is unclear (4,5,23).”
BackgroundWilliams, L. M., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1437 · Cited by 853 · cited 1×
“Two rounds of Gene Set Enrichment Analysis were performed with and without a cutoff (750-count difference between Tregs and Tconvs) and including publicly available data sets of mouse (9,10) or human (11–15) Treg/ Tconv gene expression profiles.”
MethodBattaglia, M., Stabilini, A., Migliavacca, B., Horejs-Hoeck, J., Kaupper, T., & Roncarolo, M.-G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8338 · Cited by 736 · cited 1×
“Whether peripheral T1D Tregs are able to suppress effector cell proliferation is unclear (4,5,23).”
BackgroundFetal and Adult Hematopoietic Stem Cells Give Rise to Distinct T Cell Lineages in Humans
Mold, J. E., Venkatasubrahmanyam, S., Burt, T. D., Michaëlsson, J., Rivera, J. M., Galkina, S. A., Weinberg, K., Stoddart, C. A., & McCune, J. M. (2010) · Science · doi:10.1126/science.1196509 · Cited by 444 · cited 1×
“Previous attempts to define specific markers of human Tregs focused on comparing CD25 and CD25(2) cells (11,12,21,22), thereby introducing bias toward identifying T-cell activation/memory markers rather than Tregs.”
BackgroundPlasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes
McClymont, S. A., Putnam, A. L., Lee, M. R., Esensten, J. H., Liu, W., Hulme, M. A., Hoffmüller, U., Baron, U., Olek, S., Bluestone, J. A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003099 · Cited by 428 · cited 2×
“Some evidence points to impaired Treg function in T1D (4–7), possibly related to differentiation into cells producing interleukin (IL)-17 (6) or interferon-g (7), but in vitro suppression assays may not reflect in vivo function because cells are removed from their inflammatory environment.”
BackgroundMultiparameter Immune Profiling of Operational Tolerance in Liver Transplantation
Martínez-Llordella, M., Puig-Pey, I., Orlando, G., Ramoni, M., Tisone, G., Rimola, A., Lerut, J., Latinne, D., Margarit, C., Bilbao, I., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01621.x · Cited by 374
CD4+FOXP3+ T Regulatory Cells in Human Autoimmunity: More Than a Numbers Game
Long, S. A., & Buckner, J. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003224 · Cited by 294 · cited 3×
“The proportion of CD25CD127FOXP3 Tregs in blood of subjects with T1D is normal (3); we confirmed this in a pediatric cohort (including similar levels of FOXP3 protein expression) and further showed that ex vivo Tregs from subjects with T1D have a demethylated TSDR.”
BackgroundInfluential
Cited by
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR
Zemmour, D., Zilionis, R., Kiner, E., Klein, A. M., Mathis, D., & Benoist, C. (2018) · Nature Immunology · doi:10.1038/s41590-018-0051-0 · Cited by 384
“Biclustering heatmap of published activated/resting signatures 12,66 (Bottom).”
Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?
Hull, C. M., Peakman, M., & Tree, T. I. M. (2017) · Diabetologia · doi:10.1007/s00125-017-4377-1 · Cited by 194
“…frequency of IL-17-producing cells in CD45RA−CD25intFOXP3low T cells vs NDB, which displayed reduced suppressive function Altered Treg transcriptome Pesenacker et al (2016) [37] With recent-onset T1D; with established T1D; NDB Identified a panel of genes that are differentially expressed in…”
BackgroundLakhter, A. J., Pratt, R. E., Moore, R. E., Doucette, K. K., Maier, B. F., DiMeglio, L. A., & Sims, E. K. (2018) · Diabetologia · doi:10.1007/s00125-018-4559-5 · Cited by 173
Honaker, Y., Hubbard, N., Xiang, Y., Fisher, L., Hagin, D., Sommer, K., Song, Y., Yang, S. J., Lopez, C., Tappen, T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6422 · Cited by 128
Function, Failure, and the Future Potential of Tregs in Type 1 Diabetes
Bettini, M., & Bettini, M. L. (2021) · Diabetes · doi:10.2337/dbi18-0058 · Cited by 101
Spanier, J. A., Fung, V. C. W., Wardell, C. M., Alkhatib, M. H., Chen, Y., Swanson, L. A., Dwyer, A. J., Weno, M. E., Silva, N., Mitchell, J. S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168601 · Cited by 100
Self-citationTonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion
Lamarche, C., Ward‐Hartstonge, K. A., Tian, M., Lin, D. T. S., Huang, Q. B., Brown, A., Edwards, K., Novakovsky, G., Qi, C. N., Kobor, M. S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219086120 · Cited by 93
“Furthermore, TS-CAR Tregs maintained their expected gene signature (22) and, compared to untransduced and non-TS-Car Tregs, had significantly increased expression of FOXP3 , CTLA4 , ZBRB38 , IL1R2 , and IL1RN and decreased DACT1 , ID2 , and LPIN2 , the higher and lower expression of which define…”
Self-citationImmunological biomarkers for the development and progression of type 1 diabetes
Mathieu, C., Lahesmaa, R., Bonifacio, E. E., Achenbach, P., & Tree, T. I. M. (2018) · Diabetologia · doi:10.1007/s00125-018-4726-8 · Cited by 88
Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction
Lamarthée, B., Marchal, A., Charbonnier, S., Blein, T., Léon, J., Martin, E., Rabaux‐Eygasier, L., Vogt, K., Titeux, M., Delville, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26844-1 · Cited by 89
Hoeppli, R. E., MacDonald, K. N., Leclair, P., Fung, V. C. W., Mojibian, M., Gillies, J., Rahavi, S. M. R., Campbell, A. I. M., Gandhi, S. K., Pesenacker, A. M., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.14936 · Cited by 74
Self-citationChen, P. P., Cepika, A., Agarwal, R., Saini, G., Uyeda, M. J., Louis, D. M., Cieniewicz, B., Narula, M., Amaya, L., Harre, N., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf5264 · Cited by 75
Zemmour, D., Charbonnier, L., Léon, J., Six, E. M., Keleş, S., Delville, M., Benamar, M., Barış, S., Zuber, J., Chen, K., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00910-8 · Cited by 70
Höllbacher, B., Duhen, T. M., Motley, S., Klicznik, M. M., Gratz, I. K., & Campbell, D. (2020) · ImmunoHorizons · doi:10.4049/immunohorizons.2000037 · Cited by 65
Passeri, L., Andolfi, G., Bassi, V., Russo, F., Giacomini, G., Laudisa, C., Marrocco, I., Cesana, L., Stefano, M. D., Fanti, L., et al. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103051 · Cited by 61
Rutman, A. K., Negi, S., Gasparrini, M., Hasilo, C. P., Tchervenkov, J., & Paraskevas, S. (2018) · Endocrinology · doi:10.1210/en.2018-00649 · Cited by 58
Ng, M. S. F., Roth, T. L., Mendoza, V. F., Marson, A., & Burt, T. D. (2019) · Science Immunology · doi:10.1126/sciimmunol.aav5947 · Cited by 57
Characterization of regulatory T cells in obese omental adipose tissue in humans
Wu, D., Han, J. M., Yu, X., Lam, A. J., Hoeppli, R. E., Pesenacker, A. M., Huang, Q., Chen, V., Speake, C., Yorke, E., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201847570 · Cited by 55
Self-citationOptimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human Treg identity
Lam, A. J., Lin, D. T. S., Gillies, J. K., Uday, P., Pesenacker, A. M., Kobor, M. S., & Levings, M. K. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109494 · Cited by 52
“Furthermore, using a gene signature that robustly distinguishes human Tregs from Tconvs regardless of their activation state (Pesenacker et al., 2016), FOXP3 nTregs retained characteristically high or low expression of the majority of Treg signature genes, such as CTLA4, IKZF2, IL7R, and ID2 (Figure 6C).”
Self-citationTreg gene signatures predict and measure type 1 diabetes trajectory
Pesenacker, A. M., Chen, V., Gillies, J. K., Speake, C., Marwaha, A., Sun, A. C., Chow, S., Tan, R., Elliott, T. G., Dutz, J. P., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123879 · Cited by 43
Self-citationTuomela, K., & Levings, M. K. (2024) · Diabetologia · doi:10.1007/s00125-023-06076-2 · Cited by 39
“Although peripheral blood Treg numbers are normally not affected in type 1 diabetes, their suppressive function may be reduced [2–6] and their signature gene expression profile is altered [7, 8].”
Self-citationThe role of FOXP3 in autoimmunity
Pesenacker, A. M., Cook, L. E., & Levings, M. K. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.07.004 · Cited by 39
Self-citationKeefe, R. C., Takahashi, H., Tran, L., Nelson, K. J., Ng, N., Kühtreiber, W. M., & Faustman, D. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-94529-2 · Cited by 39
Progress in Translational Regulatory T Cell Therapies for Type 1 Diabetes and Islet Transplantation
Marfil‐Garza, B. A., Hefler, J., de León, M. B., Pawlick, R. L., Dadheech, N., & Shapiro, A. M. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa028 · Cited by 36
The Multifactorial Progression from the Islet Autoimmunity to Type 1 Diabetes in Children
Bauer, W., Gyenesei, A., & Kretowski, A. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147493 · Cited by 30
Liu, Y., Powrie, J., Arif, S., Yang, J. H. M., Williams, E., Khatri, L., Joshi, M., Lhuillier, L., Fountoulakis, N., Smith, E., et al. (2022) · Diabetes · doi:10.2337/db21-0728 · Cited by 29
FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis
Régnier, P., Vétillard, M., Bansard, A., Pierre, E., Li, X., Cagnard, N., Gautier, E. L., Guermonprez, P., Manoury, B., Podsypanina, K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101256 · Cited by 30
Zhang, K., Lin, G., Han, Y., Xie, J., & Li, J. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0343-5 · Cited by 29
“Autoantibodies targeting antigens such as insulin; glutamic acid decarboxylase; protein phosphatase-like IA-2; zinc transporter-8 [7]; cytokines such as IL-1β, TNF, IFN-γ, and IFN family members; and T cell signatures [8], as well as the frequently used glucose levels, have been associated with β cell dysfunction [9].”
Imam, S., Prathibha, R., Dar, P., Almotah, K., Al-Khudhair, A., Hasan, S. A., Salim, N., Jilani, T. N., Mirmira, R. G., & Jaume, J. C. (2019) · Scientific Reports · doi:10.1038/s41598-018-38341-5 · Cited by 28
A serum- and feeder-free system to generate CD4 and regulatory T cells from human iPSCs
Fong, H., Mendel, M. C., Jascur, J., Najmi, L. A., Kim, K., Lew, G., Garimalla, S., Schock, S., Hu, J. Y., Villegas, A. G., et al. (2025) · Stem Cells · doi:10.1093/stmcls/sxaf001 · Cited by 24
Fang, C., Huang, Y., Pei, Y., Zhang, H., Chen, X., Guo, H., Li, S., Ji, X., & Hu, J. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1005-y · Cited by 23
Targeted Transcriptional Profiling of Kidney Transplant Biopsies
Sigdel, T. K., Nguyen, M., Dobi, D., Hsieh, S., Liberto, J. M., Vincenti, F. G., Sarwal, M., & Laszik, Z. G. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.01.014 · Cited by 21
A composite immune signature parallels disease progression across T1D subjects
Speake, C., Skinner, S. O., Berel, D., Whalen, E., Dufort, M. J., Young, W. C., Odegard, J., Pesenacker, A. M., Gorus, F., James, E. A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126917 · Cited by 20
Self-citationDistinguishing activated T regulatory cell and T conventional cells by single‐cell technologies
Reinhardt, J., Sharma, V., Stavridou, A., Lindner, A., Reinhardt, S., Petzold, A., Lesche, M., Rost, F., Bonifacio, E. E., & Eugster, A. (2022) · Immunology · doi:10.1111/imm.13460 · Cited by 20
“They contained 31 genes that included FOXP3 and IL7R plus a number of other genes [21].”
BackgroundUnique Features of Pancreatic-Resident Regulatory T Cells in Autoimmune Type 1 Diabetes
Lü, J., Zhang, C., Li, L., Xue, W., Zhang, C., & Zhang, X. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01235 · Cited by 18
Dissecting the role of CSF2RB expression in human regulatory T cells
Côrte‐Real, B. F., Hornero, R. A., Dyczko, A., Hamad, I., & Kleinewietfeld, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1005965 · Cited by 17
Kim, J. V., Assadian, S., Hollander, Z., Burns, P., Shannon, C. P., Lam, K., Toma, M., Ignaszewski, A., Davies, R. A., Delgado, D., et al. (2023) · Transplantation · doi:10.1097/tp.0000000000004607 · Cited by 17
“Application of the TGS in type 1 diabetes showed it was predictive of the rate of C-peptide decline.(14,15) NanoString Transcriptomic Profiling and Data”
BackgroundSelf-citationThe immune landscape of the inflamed joint defined by spectral flow cytometry
Attrill, M. H., Shinko, D., Alexiou, V., Kartawinata, M., study, C., Al‐Abadi, E., Alexiou, V., Allen, C., Armon, K., Begum, R., et al. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae071 · Cited by 17
“CD127highHelioslow cluster 14 cells could represent decreased suppressive function of Tregs in active disease [54] or activated conventional CD127high Tconv that have upregulated Foxp3 [59–62] and thus non-Treg contaminants in the Treg Foxp3 gate in PB, which was not seen in the inflamed joint.”
Hoeppli, R. E., & Pesenacker, A. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00046 · Cited by 17
Self-citationSpeake, C., Bahnson, H. T., Wesley, J. D., Perdue, N., Friedrich, D. A., Pham, M. N., Lanxon-Cookson, E. C., Kwok, W. W., Hansen, B. S., von Herrath, M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02023 · Cited by 15
Activated but functionally impaired memory Tregs are expanded in slow progressors to type 1 diabetes
Boldison, J., Long, A. E., Aitken, R. J., Wilson, I. V., Megson, C., Hanna, S. J., Wong, F. S., & Gillespie, K. M. (2021) · Diabetologia · doi:10.1007/s00125-021-05595-0 · Cited by 15
Longitudinal monitoring of gene expression in ultra-low-volume blood samples self-collected at home
Speake, C., Whalen, E., Gersuk, V. H., Chaussabel, D., Odegard, J., & Greenbaum, C. J. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12916 · Cited by 14
Role of regulatory T cells in Schistosoma-mediated protection against type 1 diabetes
Tang, C., Gao, Y.-R., Wang, L.-X., Zhu, Y., Pan, Q., Zhang, R.-H., & Xiong, Y. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.04.014 · Cited by 15
RefBool: a reference-based algorithm for discretizing gene expression data
Jung, S., Hartmann, A., & del Sol, A. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx111 · Cited by 13
“The analysis of these datasets has led to numerous biological insights, like cell type specific gene signatures (Ko et al., 2013; Palmer et al., 2006; Pont et al., 2016; Pesenacker et al., 2016).”
BackgroundSoussi, S., Maione, A. S., Lefèvre, L., Pizzinat, N., Iacovoni, J. S., Gonzalez-Fuentes, I., Cussac, D., Iengo, L., Santin, Y., Tundo, F., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07364-y · Cited by 11
Keretsu, S., Hana, T., Lee, A., Kedei, N., Malik, N., Kim, H. M., Spurgeon, J., Khayrullina, G., Ruf, B., Hara, A., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf173 · Cited by 11
Nucleic acid biomarkers of β cell stress and death in type 1 diabetes
Syed, F., & Evans‐Molina, C. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000261 · Cited by 11
Regulatory T cells: master orchestrators of immune tolerance and tissue homeostasis
Bluestone, J. A., Levings, M. K., Ramsdell, F. J., Rudensky, A. Y., Tang, Q., & Trzonkowski, P. (2026) · Frontiers in Science · doi:10.3389/fsci.2026.1792210 · Cited by 10
Self-citationMallu, A. C. T., Vasudevan, M., Allanki, S., Nathan, A. A., Ravi, M. M., Ramanathan, G. S., Pradeepa, R., Mohan, V., & Dixit, M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.08.007 · Cited by 9
Transcriptional fingerprinting of regulatory T cells: ensuring quality in cell therapy applications
Cheng, Z., Wang, L., Honaker, Y., Cincotta, S. A., Page, C. E., Vollhardt, S., Yuan, V., Long, S. A., Xiao, Y., Beilke, J. N., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1602172 · Cited by 8
Treg fitness signatures as a biomarker for disease activity in Juvenile Idiopathic Arthritis
Attrill, M. H., Shinko, D., Viveiros, T. M., Milighetti, M., de Gruijter, N. M., Jebson, B. R., Kartawinata, M., Rosser, E. C., Wedderburn, L. R., study, C., et al. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103379 · Cited by 8
“…governing this model suggests a possible shift towards a more effector-like signature in JIA Tregs, with expression of genes usually upregulated in Tregs compared to effector T cells, such as TRIB1, CSF2RB, ZC2HC1A, HPGD and STAM [31,57], represented more in a HC Treg signature than JIA PB Tregs.”
InfluentialSelf-citationHornero, R. A., Aegerter, H., Hamad, I., Côrte‐Real, B. F., Staes, K., van der Woning, B., Verstraete, K., Savvides, S. N., Lambrecht, B. N., & Kleinewietfeld, M. (2022) · Allergy · doi:10.1111/all.15332 · Cited by 8
Bi, Y., Kong, R., Peng, Y., Yu, H., & Zhou, Z. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109716 · Cited by 7
Amodio, D., Angelidou, A., Cotugno, N., Sherman, A. C., Levy, O., Palma, P., Pollard, A. J., Damme, P. V., Rappuoli, R., Goulder, P., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126477 · Cited by 6
“Insights from asthma, diabetes and heart transplantation studies revealed involvement of Treg cells in inflammatory responses and acute rejection monitoring [71,72].”
Self-citationContext-Dependent Effects Explain Divergent Prognostic Roles of Tregs in Cancer
Amblard, E., & Soumelis, V. (2022) · Cancers · doi:10.3390/cancers14122991 · Cited by 6
Identifying the ‘Achilles heel’ of type 1 diabetes
Battaglia, M., Buckner, J. H., Levings, M. K., Richardson, S. J., Wong, F. S., & Tree, T. I. M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13570 · Cited by 6
“These data showed that Tregs from both children and adults with T1D have changes in their core transcriptional signature, and that monitoring this signature can be used to track changes in Tregs over time in the context of clinical trials (70,71).”
BackgroundSelf-citationCirculating pancreatic enzyme levels are a causal biomarker of type 1 diabetesPreprint
Elgamal, R. M., Melton, R. L., Chiou, J., McGrail, C., & Gaulton, K. J. (2024) · medRxiv · doi:10.1101/2024.08.08.24311619 · Cited by 4
“1b, Supplementary Table 6) .”
BackgroundInfluentialHuang, L., Wang, Y., Li, C., Wang, X., Xiao, A., Han, F., & Jiang, J. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08834-7 · Cited by 3
Du, Z.-Z., Ling, Y., Tong, H.-G., Guo, X.-L., & Teschendorff, A. (2026) · Nature Communications · doi:10.1038/s41467-026-76038-w · Cited by 2
New TREG gene signature for T1DM
Geach, T. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.19 · Cited by 2
Kp, Z., Popov, V. V., Gruzov, M. A., Bm, K., Vv, A., Malynovskaya, T. N., Tronko, E. N., Saienko, Y. A., Semionova, T. A., & Kulskovskaya, A. B. (2017) · Endokrynologia · Cited by 2
Autoimmune Endocrine Disorders
Barker, J. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-73782-9_34 · Cited by 2
Geng, Y., Zhang, Y., Xu, X., Wang, Y., Luo, Y., & Sun, X. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01613-z · Cited by 1
“TNFRSF1B has been identified as a specific and sensitive biomarker in regulatory T cells of children with Type 1 Diabetes (T1D) [26].”
Joseph, A., Nair, L. C. R., Johnson, B. S., Thomas, P. L., Padmanabhan, R. A., Puthumadathil, N., & Laloraya, M. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000010 · Cited by 1
Autoimmune Endocrine Disorders
Barker, J. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_35 · Cited by 1
Cellular Immunological Mechanisms Contributing to Diabetes Pathogenesis
Radenkovic, M. (2016) · Lund University Publications (Lund University)
Role of regulatory T cells in obesity and insulin resistance
Wu, D.-Y. (2019) · Joint Conference of the Information Retrieval Communities in Europe · doi:10.14288/1.0384589
Oliveira, J. E. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2024.tde-26072024-134154
Carroll, K. R. (2018) · OhioLink ETD Center (Ohio Library and Information Network)
Tim-3+ Treg control viral persistence and effector T cell responses.
Nieves-Rosado, H. M. (2024) · D-Scholarship@Pitt (University of Pittsburgh)
Extracellular vesicles as modulators of auto- and alloimmune responses
Rutman, A. K. (2025) · eScholarship@McGill (McGill) · doi:10.82308/24851
Phetsouphanh, C., Cook, L., Jackson, K., Cuff, D. E., Klemm, V., Manandhar, B., Hsu, D. C., Xu, Y., Zaunders, J., Kelleher, A. D., et al. (2026) · Immunology and Cell Biology · doi:10.1111/imcb.70148
Stealth CAR-Tregs evade CD3 antibody therapy and skew immune responses toward regulationPreprint
Blein, T., Ayas, N., Charbonnier, S., Gil, A., Haddouche, A., Hassan, J., Rabaux, L., Andre, I., Waldmann, H., Lamarthée, B., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.13.758862
Supporting information 1 of Dissecting the role of CSF2RB expression in human regulatory T cells
Côrte-Real, B. F., Hornero, R. A., Dyczko, A., Hamad, I., & Kleinewietfeld, M. (2022) · doi:10.3389/fimmu.2022.1005965.s001
Metadata
- Authors
- Pesenacker, A. M., Wang, A. Y., Singh, A., Gillies, J., Kim, Y., Piccirillo, C. A., Nguyen, D., Haining, W. N., Tebbutt, S. J., Panagiotopoulos, C., & Levings, M. K.
- Affiliations
- University of British Columbia (CA)
- McGill University (CA)
- Broad Institute (US)
- Corresponding author
- Levings, Megan K.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2016-01-19
- Volume
- 65
- Issue
- 4
- Pages
- 1031-1039
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2305631593
- Cited by
- 69
- References
- 36
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 5 · 2021: 9 · 2020: 5 · 2019: 9 · 2018: 8 · 2017: 5 · 2016: 5
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes for Health Research (MOP-115199)
- Canucks for Kids Foundation
- Genome BC
- Genome Quebec
- Stemcell Technologies
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 1 diabetes, regulatory T cells, gene expression signatures, biomarkers, new-onset diabetes, children, TNF receptor 2, Foxp3, autoimmunity, disease progression monitoring, NanoString nCounter
- MeSH terms
- Adult, Cells, Cultured, Child, Diabetes Mellitus, Type 1, Humans, Male, Mass Screening, Sensitivity and Specificity, Biomarkers, Autoimmunity, Case-Control Studies, Age of Onset, Disease Progression, T-Lymphocytes, Regulatory, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.